CAR T-Cell Therapy for Advanced Gastrointestinal Stromal Tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized immune cell therapy made from your own tumor-fighting white blood cells, combined with a medication called interleukin-2, to treat gastrointestinal stromal tumors (GIST) that have spread or cannot be surgically removed. The goal is to help your immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have measurable GIST that is locally advanced, recurrent, or metastatic (spread to distant sites)
- If your cancer has spread distantly, you must have already tried and failed standard drug treatments like imatinib or sunitinib
- You must be 18–75 years old and in good enough health to tolerate treatment (ECOG performance status 0 or 1)
- Your blood counts and organ function must meet specific minimums (checked by lab tests)
- You cannot be pregnant or breastfeeding, and must use birth control for 4 months after treatment
- You must be HIV-negative and free of hepatitis B and C infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
This trial tests a new type of immune cell therapy called CBG131 CAR-T cells for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. The therapy targets a protein called CLDN18.2 on cancer cells, and the study aims to see if it can shrink tumors.
Hear when a new Locally Advanced Gastrointestinal Stromal Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.